BioSpace News Archive

Pharm Country

HUTCHMED Receives Approval to Commercialize ELUNATE® in MacauFirst homegrown innovative medicine approved in Macau based on China clinical data

HUTCHMED Limited announces that it has received approval to market fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors 1, 2 and 3, in the Macau Special Administrative Region.

March 1, 2022
·
9 min read
Genetown

BeiGene to Present at the Cowen 42nd Annual Health Care Virtual Conference

BeiGene announced that the Company will participate in the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 9:50 a.m. ET.

March 1, 2022
·
1 min read
Drug Development

CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion

CatalYm announced treatment of the first patients in a series of phase 2a cohorts targeting solid tumors, initiating phase 2 development of CTL-002.

March 1, 2022
·
6 min read
Business

Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

Zynerba Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year ended December 31, 2021, and provided an overview of recent operational highlights and a pipeline update.

March 1, 2022
·
10 min read
Business

Amarin Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Amarin Corporation plc, announced financial results for the quarter and year ended December 31, 2021 and provided an update on company operations.

March 1, 2022
·
29 min read
Business

BioAtla Announces Fourth Quarter And Full Year 2021 Financial Results

BioAtla, Inc. announces its financial results for the fourth quarter and full year December 31, 2021, and provides an update on product pipeline developments.

March 1, 2022
·
12 min read
Business

RadNet Reports Fourth Quarter 2021 Results and Releases 2022 Financial Guidance

RadNet, Inc. reported financial results for its fourth quarter and full year ended December 31, 2021.

March 1, 2022
·
33 min read
Business

Carmot announces Tim Garnett M.D., previously Chief Medical Officer Eli Lilly, joins Carmot’s Board of Directors

Carmot Therapeutics, Inc., a clinical-stage biotechnology company applying its proprietary platform, Chemotype Evolution, to discover and develop disease-modifying therapies in metabolic disease and cancer, announced a key addition to its Board of Directors.

March 1, 2022
·
2 min read
Bio NC

Pathalys Pharma, Inc. Launches with Mission to Address High Priority Needs in Chronic Kidney Disease

Pathalys Pharma, Inc. announced its formation made possible through initial seed financing from DaVita Venture Group, part of DaVita Inc., and Catalys Pacific.

March 1, 2022
·
7 min read
BioMidwest

Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03

Acura Pharmaceuticals, Inc. announced an amendment to its License, Development and Commercialization Agreement regarding Acura’s LIMITx™ LTX-03 product candidate with Abuse Deterrent Pharmaceuticals, LLC to extend the FDA Acceptance Date for LTX-03 to December 31, 2022.

March 1, 2022
·
6 min read